Healthcare Distributor Loyalty: AKS-Compliant Channel Incentive Design

Healthcare Distributor Loyalty Programs: Designing Compliant Channel Incentives Under the Anti-Kickback Statute

A channel incentive program that would be entirely uncontroversial in automotive, building materials, or consumer goods becomes a federal compliance matter the moment the distributor's downstream customer is a hospital, ambulatory surgical center, or physician practice that bills federal healthcare programs. The mechanism is the Anti-Kickback Statute (AKS), 42 U.S.C. § 1320a-7b(b), which prohibits offering, paying, soliciting, or receiving anything of value intended to induce or reward referrals of items or services reimbursable by Medicare, Medicaid, or other federal healthcare programs.

The commercial logic of a channel incentive program is sound: reward the distributor rep who drives product adoption, accelerate new-account development, recognize the distributor who achieves category targets. The compliance challenge is that distributor personnel in the healthcare sector frequently have direct or indirect contact with the healthcare professionals who make or influence product-selection decisions. When the reward structure is connected, even indirectly, to behaviors that touch federally reimbursable purchasing decisions, the AKS exposure is real.

The practical consequence: medical device manufacturers, pharmaceutical manufacturers, and healthcare product companies that run channel incentive programs for their distributor networks must design those programs against a compliance framework that does not apply to any other B2B incentive context. The reward catalog is a compliance decision. The eligible behaviors are a compliance decision. The participant eligibility criteria, specifically which distributor personnel can participate, is a compliance decision. Getting these decisions right before launch is dramatically less expensive than restructuring an active program after legal review identifies exposure.

This article maps the regulatory landscape governing healthcare distributor incentive programs (the AKS, the Physician Payments Sunshine Act, OIG safe harbors, AdvaMed Code principles, and the recent enforcement guidance that narrows what was previously considered safe) and provides a compliance-anchored design framework that program owners can use to structure programs that are both commercially effective and legally defensible.

The Regulatory Landscape: AKS, Sunshine Act, and OIG Safe Harbors

The Anti-Kickback Statute

The AKS is a federal criminal statute that prohibits the knowing and willful offer, payment, solicitation, or receipt of anything of value, termed remuneration, intended to induce or reward referrals of items or services reimbursable by federal healthcare programs including Medicare and Medicaid. The breadth of the statute's coverage is intentional: remuneration is interpreted broadly to include virtually anything of value, such as cash, goods, services, discounts, entertainment, and non-cash rewards.

Several features make the AKS particularly consequential for channel incentive design. First, intent: unlike the Stark Law, which is a strict-liability statute, the AKS requires proof of knowing and willful intent. Many courts, however, apply the 'one purpose' test, under which the statute is violated if even one purpose of a payment is to induce referrals, regardless of other legitimate purposes. Second, scope: the AKS reaches not only direct payments to physicians or other referral sources, but any remuneration that could induce referrals, including payments to distributors whose downstream sales activities touch federally reimbursable items. Third, consequences: AKS violations are felonies, punishable by a maximum fine of $100,000 and up to 10 years of imprisonment per violation, along with civil monetary penalties and exclusion from federal healthcare programs. False Claims Act exposure can attach to every claim submitted as a result of an AKS-tainted arrangement.

OIG Safe Harbors

The OIG has published safe harbor regulations specifying arrangements that, if all conditions are met, will not be treated as AKS violations. Safe harbors are voluntary: failure to qualify does not automatically constitute a violation, but it exposes the arrangement to full OIG scrutiny. Three safe harbors are most relevant to healthcare channel incentive programs.

Personal Services and Management Contracts Safe Harbor. Protects compensation for legitimate services when the compensation is set in advance, is consistent with fair market value, is not determined in a manner that takes into account the volume or value of referrals or other business generated between the parties, and the aggregate services do not exceed those reasonably necessary for a commercially reasonable business purpose (42 C.F.R. § 1001.952(d)).

Employee Safe Harbor. Payments to bona fide employees as employment compensation are protected. Distributor reps who are employees of a manufacturer's own distribution subsidiary may qualify; independent distributor personnel typically do not.

Discount Safe Harbor. Protects discounts or price reductions obtained by a provider if properly disclosed and appropriately reflected in the costs the provider claims. OIG has recognized tiered volume-based rebate structures for durable medical equipment suppliers when the structure is based solely on purchase volume, not on the conversion of specific patients to federally reimbursable products, and when it is properly documented and disclosed.

OIG Advisory Opinion 25-08: Fixed Fee Structures Are Not Automatically Safe

On July 7, 2025, the OIG published Advisory Opinion 25-08, an unfavorable opinion that clarified the limits of the Personal Services and Management Contracts Safe Harbor. The opinion addressed a proposed arrangement in which a medical device company that supplies 'bill-only' surgical devices to hospitals and ASCs would pay a third-party vendor per-representative licensing fees, approximately $395 per license and roughly $1.2 million a year in aggregate, to access an electronic billing portal used by some of the company's provider customers.

The OIG concluded the arrangement would generate prohibited remuneration. The critical fact was redundancy: the device company already had its own accounts-receivable processes, so the portal provided it no tangible independent benefit. Because the fees were therefore not commercially reasonable, the only real benefit the company obtained was retaining and potentially expanding business (that is, accessing referrals) from the providers who used the portal. The OIG also flagged that the arrangement could inappropriately steer providers toward manufacturers willing to pay the vendor's fees, an anti-competitive concern. Because the company could not certify that the services were reasonably necessary to accomplish a commercially reasonable business purpose, the arrangement failed the Personal Services and Management Contracts Safe Harbor.

The implication for channel incentive programs: any arrangement whose primary function is to motivate distributor behavior that generates referrals of federally reimbursable items, rather than to compensate legitimate, identifiable commercial activities at documented fair market value, carries AKS exposure regardless of how the fee is structured. A fixed or flat fee does not cure a structure whose real purpose is to access referrals.

The Seventh Circuit's Sorensen Decision (April 2025)

On April 14, 2025, the Seventh Circuit decided United States v. Sorensen (No. 24-1557, 134 F.4th 493), reversing the AKS conviction of the owner of a Medicare-registered durable medical equipment distributor. The distributor paid marketing firms based on the number of leads generated and paid a manufacturer a percentage of Medicare reimbursement, to advertise orthopedic braces to patients. Physicians received prefilled but unsigned prescription forms and ignored roughly 80 percent of them.

The court held these payments were not 'referrals' under the AKS because the marketing firms were neither physicians in a position to refer patients nor other decision-makers able to 'leverage fluid, informal power and influence' over healthcare decisions, and because the physicians retained full independent judgment (the court described the advertising as 'proposals for care,' not referrals). The court also noted that percentage-based compensation is not automatically unlawful absent intent to induce referrals.

Sorensen is meaningful for healthcare marketing arrangements, but its implications for channel incentive programs are more limited. A distributor rep whose rewards are tied to sales of products used in federally reimbursable procedures, and who has direct contact with the clinicians selecting those products, is in a very different position from a marketing firm that generates leads without influencing clinical decisions. Program designers should not read Sorensen as broadly permitting channel incentive arrangements that reward distributor personnel for behaviors closely tied to the clinical adoption of reimbursable products.

The Physician Payments Sunshine Act and Open Payments

The Physician Payments Sunshine Act requires applicable manufacturers of drugs, devices, biologicals, and medical supplies to track and publicly report transfers of value to covered recipients (physicians, certain other clinicians, and teaching hospitals) through CMS's Open Payments program. The obligation applies to transfers of value above a de minimis threshold, including direct and indirect payments made through third parties.

For channel incentive programs, the reporting obligation is triggered when value flows through a distributor to a covered recipient, for example a physician who participates in a distributor incentive program funded by the manufacturer. The Medtronic settlement is the documented cautionary example. In 2020, Medtronic USA agreed to pay $9.2 million to resolve allegations that it paid for more than 130 social events at a restaurant owned by a South Dakota neurosurgeon in order to induce him to use its implantable infusion pumps ($8.1 million to resolve the Anti-Kickback Statute and False Claims Act allegations), and that it underreported those transfers of value to CMS ($1.11 million to resolve the Open Payments allegations). It was the first public enforcement action under the Open Payments program, and Medtronic settled without admitting liability. Program structures that route manufacturer incentive value through distributors to HCPs must be evaluated for Sunshine Act reporting obligations with the same rigor applied to direct manufacturer-to-HCP arrangements.

AdvaMed Code Alignment: Industry Standards for Channel Partner Interactions

The AdvaMed Code of Ethics on Interactions with U.S. Health Care Professionals establishes standards for how medical device companies interact with HCPs. While the Code is primarily directed at direct manufacturer-to-HCP interactions, its principles extend to interactions conducted through channel partners (distributors, dealers, and rep firms) whose personnel interact with clinical staff.

The Code's core principle: any transfer of value to or through channel partners must be for a legitimate business purpose, must be reasonable in amount, and must not be intended to induce or reward the clinical selection of the manufacturer's products for use in federally reimbursable procedures. AdvaMed Code alignment is the industry standard that sophisticated buyers and hospital systems use to evaluate vendor relationships, and it is increasingly cited in OIG guidance and enforcement as evidence of what compliant program design looks like. Three principles are directly relevant to channel incentive design:

Payments for services. Payments to HCPs for consulting, speaking, or other legitimate services must be at fair market value and must not take into account the volume or value of business the HCP generates. This extends to any arrangement that flows through a distributor to an HCP.

Training and education. Support must be for bona fide educational purposes, must not be conditioned on past or expected purchasing behavior, and must be organized and managed independent of the sales and marketing function.

Entertainment and recreation. These are not appropriate vehicles for relationship-building or product promotion. Any distributor incentive program that funds entertainment for HCP contacts (dinners, sporting events, recreational outings) through its reward catalog or event structure creates AdvaMed Code exposure even if the entertainment is provided by the distributor rather than the manufacturer directly.

The Compliant Design Framework: Four Principles for AKS-Safe Healthcare Channel Incentives

Principle 1: Tether Rewards to Commercial Activities, Not Reimbursable Procedures

The foundational compliance design decision is identifying which distributor behaviors the program rewards, and confirming that those behaviors are commercial activities rather than clinical-adoption behaviors tied to federally reimbursable procedures. This is the principle we apply in our own program-design work: rewards should be tethered to legitimate commercial activities, such as training completions, demo scheduling, and new-account development, rather than to the volume of federally reimbursable procedures performed. The logic tracks the safe-harbor requirement that compensation not be determined by the volume or value of referrals.

Compliant reward-eligible behaviors: new account identification and qualification (commercial development, not clinical selection); product demo scheduling and facilitation (commercial activity preceding clinical evaluation, not the evaluation itself); training completions, both internal and customer-facing educational sessions organized and managed independently of sales; new product-category introduction with documented customer engagement; and contract execution or renewal milestones.

Behaviors that require careful structuring or exclusion: total product revenue in a period where the revenue is derived from procedures that are primarily federally reimbursable; any behavior that could be characterized as inducing a specific clinical product selection for a specific patient; and activities that reward distributor reps for facilitating HCP interactions where the incentive value flows through to the HCP.

Principle 2: Document Fair Market Value for All Reward Values

Every transfer of value in a healthcare channel incentive program must be defensible against a fair market value standard. The OIG's framework consistently emphasizes that compensation, whether a direct payment or non-cash reward value, must not exceed what a commercially reasonable party would pay for the services rendered, absent the referral relationship. In practice this means:

• Establishing a per-participant annual value cap before launch, based on a documented analysis of what comparable participants receive for similar commercial activities, independent of any referral relationship.
• Documenting the fair market value basis for each reward tier. If a Gold-tier distributor is eligible for rewards with an annual value ceiling (for example, an illustrative $2,500), the documentation should reflect why that ceiling is reasonable fair market value for the commercial activities required to reach the tier. The specific figure is illustrative and should be set by each program's own analysis.
• Ensuring reward values do not escalate proportionally with revenue in a way that effectively creates a percentage-of-sales structure. A fixed reward for completing a training milestone is defensible; a reward that scales directly with the revenue generated by the trained rep's subsequent sales looks more like a referral fee.

Principle 3: Apply Elevated Scrutiny to Cash and Near-Cash Rewards for HCP-Adjacent Participants

The reward catalog is one of the most consequential compliance decisions in healthcare channel incentive design, and one of the most frequently overlooked. Cash and near-cash rewards (prepaid cards, gift cards usable at any retailer, checks, bank transfers) carry elevated AKS scrutiny because they are the most direct form of remuneration and the hardest to distinguish from a straightforward payment for referrals.

For distributor personnel who have direct contact with clinical staff or who influence product selection at hospitals or ASCs, the compliant standard is a non-cash, points-redeemable catalog of merchandise and experiences with documented per-item and per-participant annual value limits. This is the same standard we hold to in our own guidance: cash and near-cash rewards carry higher compliance scrutiny, any reward construct should be documented against a fair market value standard, and per-participant annual value limits should be established before launch.

Compliant catalog construction: merchandise (branded goods, electronics, home goods) with individual item-value documentation; experiential rewards (travel, events) where the experience is personal and recreational rather than clinical entertainment for HCP contacts; educational benefits that are genuinely educational and independently managed; and recognitional programs (President's Club, achievement awards) with documented value. Excluded: gift cards usable as cash equivalents, cash or cash-equivalent payments, entertainment for HCP contacts, and any reward that flows through to a covered recipient without Sunshine Act tracking.

Principle 4: Build Governance Infrastructure Before Launch

The failure mode that generates the most significant legal exposure is treating compliance as a post-design legal review rather than a design input. Programs designed by commercial teams, launched into the market, and only then submitted for compliance review consistently produce one of two outcomes: significant restructuring at or immediately after launch, or continued operation without adequate compliance infrastructure that accumulates risk over time.

The governance infrastructure that should exist before a healthcare channel incentive program launches: qualified healthcare compliance counsel has reviewed the program structure and reward design against current AKS guidance and applicable OIG advisory opinions; participant eligibility has been evaluated with specific attention to which distributor personnel have contact with covered recipients; the reward catalog has been reviewed for cash and near-cash exposure and documented against fair market value standards; a monitoring protocol exists for tracking per-participant annual reward accumulation against the value cap; and the Sunshine Act tracking obligation has been evaluated for any reward flows that could be characterized as indirect transfers of value to covered recipients.

Compliant vs. High-Risk Program Design Elements

Participant Eligibility: The Most Consequential Compliance Decision

Who can participate in a healthcare channel incentive program is, in practice, the compliance decision with the greatest impact on AKS exposure. The risk is concentrated in the subset of distributor personnel whose roles involve direct contact with HCPs or direct influence over clinical purchasing decisions. A program that carefully controls eligibility, including only personnel whose commercial activities are genuinely separable from clinical influence, substantially reduces AKS exposure before reward design is even considered.

For each category of distributor personnel eligible to participate, the program owner should be able to answer three questions affirmatively. Do these individuals primarily perform commercial activities (logistics, contract management, account development, sales operations) rather than clinical activities (direct engagement with HCPs about product selection for specific patients)? Is their distributor compensation not itself structured to create incentives tied to the volume of federally reimbursable procedures? Is the reward value they will accumulate documented against a fair market value standard for the commercial activities they perform?

If the answer to any of these is no, qualified legal counsel must evaluate whether the category can be included and, if so, what additional constraints apply. Including categories where the answer is no, without that legal evaluation, is the most common source of post-launch program restructuring in healthcare channel incentive programs.

Pharmaceutical vs. Medical Device Distributor Programs: Key Differences

While the AKS framework applies broadly across pharmaceutical and medical device channel incentive programs, the specific risk profile differs between the two sectors in ways that affect design.

Medical device distributor programs typically involve reps who work directly in clinical environments (operating rooms, procedure suites, catheterization labs) alongside the HCPs performing the procedures. That clinical presence creates direct exposure: a rep who is present during procedures and is rewarded for the volume of procedures using the manufacturer's device is in a position that demands extremely careful program design. The Medtronic matter is the cautionary case, where a manufacturer funded events connected to a physician's product adoption and incurred both AKS and Sunshine Act liability.

Pharmaceutical distributor programs (wholesalers, specialty distributors, pharmacy networks) typically involve personnel further removed from the clinical decision, managing shipping, stocking, and supply chains rather than participating in clinical environments. This does not eliminate AKS exposure. The Discount Safe Harbor's requirements apply to pharma distributor rebate structures, and any arrangement that rewards pharmacy personnel for switching or recommending specific drug products to patients or prescribers requires careful AKS analysis. But proximity to the clinical decision is generally more attenuated.

Both sectors require compliance-first design. The device sector requires more stringent attention to participant eligibility, clinical presence, and Sunshine Act tracking because of the closer physical proximity of distributor personnel to the clinical environment.

Conclusion

Healthcare channel incentive programs are not a niche compliance challenge. They are a standard commercial tool in the medical device and pharmaceutical industries that requires compliance infrastructure not present in any other B2B incentive context. The companies that design these programs well do two things that distinguish their approach: they treat compliance as a design input rather than a post-design review, and they recognize that the reward catalog, participant eligibility, and behavior-to-reward linkage are each compliance decisions, not just commercial choices.

The regulatory environment in 2025 and 2026 has become more nuanced in important ways. The Seventh Circuit's Sorensen decision provides relief for marketing arrangements where marketing firms do not directly influence clinical decisions. OIG Advisory Opinion 25-08 confirms that structural choices, such as fixed fee versus volume-based, do not by themselves determine compliance; the underlying purpose and the commercial value provided determine whether an arrangement is defensible. Together, these developments point toward a regulatory direction that rewards programs with genuine, documented commercial rationale and penalizes programs whose primary purpose is generating referral volume regardless of fee structure.

The program that survives an OIG inquiry is the one that can demonstrate, for every design choice, why that choice serves a legitimate commercial purpose, why the reward value is proportionate to fair market value for the activity performed, and why the structure could not reasonably be characterized as inducing referrals of federally reimbursable products. Building that demonstrability into the program before launch, through qualified legal review, documented fair market value analysis, participant eligibility evaluation, and governance infrastructure, is the investment that prevents restructuring and enforcement exposure after launch.